Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

April 13, 2009 updated by: University of Pennsylvania

The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID

The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1865

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Phila, Pennsylvania, United States, 19104
        • Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
No Intervention: Standard practice
The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Decreased rate of prescription of the combination of warfarin and NSAID
Time Frame: 17 months
17 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2006

Primary Completion (Actual)

December 1, 2007

Study Completion (Actual)

December 1, 2007

Study Registration Dates

First Submitted

April 13, 2009

First Submitted That Met QC Criteria

April 13, 2009

First Posted (Estimate)

April 14, 2009

Study Record Updates

Last Update Posted (Estimate)

April 14, 2009

Last Update Submitted That Met QC Criteria

April 13, 2009

Last Verified

April 1, 2009

More Information

Terms related to this study

Other Study ID Numbers

  • 803787

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Warfarin and NSAID

Clinical Trials on Electronic Alert

3
Subscribe